The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC

约翰霍普金斯大学转化免疫工程 (JH-TIE) BTRC

• 批准号: 10223291
• 负责人: JONATHAN P SCHNECK
• 金额: $ 115.03万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10223291
• 关键词: Advisory Committees; Antigen-Presenting Cells; Autoimmune Diseases; Back; Biocompatible Materials; Biological Response Modifier Therapy; Biology; Biomedical Engineering; Capital; Cell Therapy; Cells; Cellular immunotherapy; Clinic; Clinical; Collaborations; Communicable Diseases; Communication; Communities; Cytotoxic T-Lymphocytes; Development; Devices; Disease; Educational Curriculum; Educational workshop; Engineering; Event; Foundations; Funding; Gene Transfer; Generations; Genetic; Geography; Goals; Healthcare; Immune; Immune system; Immunologist; Immunology; Immunotherapy; Industrialization; Inflammatory; Infrastructure; Institutes; International; Jordan; Knowledge; Lead; Libraries; Life; Malignant Neoplasms; Metabolic; Methodology; Microscopy; Mission; Modification; Neurodegenerative Disorders; Nomenclature; Oncology; Online Systems; Outcome; Participant; Pathology; Population; Process; Protocols documentation; Public Health; Publications; Regenerative Medicine; Regulatory T-Lymphocyte; Research; Research Personnel; Resources; Savings; Scientific Advances and Accomplishments; Scientist; Seasons; Services; Students; T-Lymphocyte; Techniques; Technology; Therapeutic; Tissue Engineering; Training; Training Programs; Translational Research; Translations; United States National Institutes of Health; Work; base; cancer therapy; cellular engineering; certificate program; conflict resolution; design; extracellular; graduate student; immunoengineering; improved; in vivo; infectious disease treatment; inhibitor/antagonist; innovation; leadership development; nano; nanobiotechnology; next generation; novel; outreach; particle; posters; regenerative therapy; research and development; scale up; small molecule; symposium; technology research and development; technology/technique; therapy development; tool; treatment optimization; web site

Overall – Summary Research in immunology has created stunning scientific advances that have the potential to revolutionize regenerative medicine, infectious disease, autoimmune disorders, neurodegenerative disease, and cancer. Yet, innovations remain in the lab, not realizing their clinical potential. Immunologists develop therapies that focus on fundamental mechanistic biology but lack tools to optimize therapies. Engineers bring a quantitative approach and highly optimized devices and treatments, but often avoid the immune system entirely, rather than trying to harness it. A profound gap exists between engineering and immunology, one that has held back life-saving innovations from reaching the clinic. The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC will serve as a thought leader and collaborative hub for immunoengineering research. JH-TIE will bring together the worlds of engineering and immunology, leading the research and development of transformative cancer therapies and regenerative medicine. JH-TIE's goals include: • Develop products, techniques, and methodologies to streamline the stimulation and expansion of functional T cells to provide a greater number of therapeutic cells faster and with greater proliferative potential, including a GMP-compliant batching methodology for scale-up; • Develop new enabling technologies, techniques, and products for more effective stimulation and modification of immune cells, including via biomaterials-based gene transfer and use of novel small molecule activators and inhibitors; • Develop new biotherapeutics for cellular engineering to increase T cell efficacy in vivo, including increased robustness of cytotoxic T cells against immunosuppressive counter-effects as well as complementary technology to engineer regulatory T cells for potential use for autoimmune diseases; • Expand the reach of immunoengineering principles by offering training courses, seminars, and curricula for researchers, industrial practitioners, clinicians, and students, including a new certificate program in immunoengineering for graduate students; • Advance the field of immunoengineering by hosting conferences, short courses, and other targeted offerings; • Serve as an interface and liaison for communities of engineers, immunologists, and other stakeholders. Three Technology Research and Development (TR&D) projects that will serve as a foundation for the JH-TIE center. Each TR&D is designed to deliver a technical service platform in support of a diverse community of end users. JH-TIE will provide training and dissemination of key technologies and techniques developed to collaborators and the broader research community. Collaborative and service projects are proposed in conjunction with this effort to broaden the technologies' impact. JH-TIE will expand on standard dissemination by hosting local workshops and classes, international seminars, and web-based tutorials. The JH-TIE will lead a paradigm shift and grow the field of immunoengineering. JH-TIE will achieve this through world-class research and by broadly engaging a diverse set of stakeholders. Together, these efforts will advance the field of immunoengineering, enabling new cell-based and regenerative therapies to reach the clinic, and training a generation of new immunoengineering practitioners.

总体-总结 免疫学研究创造了惊人的科学进步，有可能彻底改变 再生医学、传染病、自身免疫性疾病、神经变性疾病和癌症。 然而，创新仍然停留在实验室中，没有实现其临床潜力。免疫学家开发的疗法 专注于基本的机械生物学，但缺乏优化疗法的工具。工程师带来了一个定量的 方法和高度优化的设备和治疗，但往往完全避开免疫系统， 而不是试图利用它。工程学和免疫学之间存在着深刻的差距， 将拯救生命的创新带到诊所。 约翰霍普金斯转化免疫工程（JH-TIE）BTRC将作为思想领袖 和免疫工程研究的协作中心。JH-TIE将汇集世界各地的 工程学和免疫学，领导变革性癌症疗法的研究和开发， 再生医学JH-TIE的目标包括： ·开发产品，技术和方法，以简化刺激和扩展 功能性T细胞，以更快地提供更多数量的治疗性细胞， 增殖潜力，包括符合GMP的扩大规模的生物技术方法; ·开发新的使能技术、工艺和产品，以实现更有效的刺激和 免疫细胞的修饰，包括通过基于生物材料的基因转移和使用新的小 分子活化剂和抑制剂; ·开发用于细胞工程的新生物治疗药物，以增加体内T细胞功效，包括 增加细胞毒性T细胞对抗免疫抑制反作用的稳健性，以及 工程化调节性T细胞的互补技术，用于自身免疫性疾病的潜在用途; ·通过提供培训课程、研讨会和 为研究人员、工业从业人员、临床医生和学生提供的课程，包括一个新的证书 研究生免疫工程专业; ·通过举办会议、短期课程和其他有针对性的活动，推动免疫工程领域的发展。 产品; ·作为工程师，免疫学家和其他社区的接口和联络人 持份者 三个技术研发（TR&D）项目将作为JH-TIE的基础 中心每个TR&D都旨在提供一个技术服务平台，以支持多样化的终端社区 用户. JH-TIE将为合作者提供关键技术和技术的培训和传播 和更广泛的研究社区。协同和服务项目与此同时提出 努力扩大技术的影响。JH-TIE将通过举办当地的 讲习班和课程、国际研讨会和基于网络的教程。 JH-TIE将引领范式转变，并发展免疫工程领域。JH-TIE将实现这一目标 通过世界一流的研究和广泛参与各种利益相关者。总之，这些努力 将推进免疫工程领域，使新的基于细胞的和再生的疗法，以达到 临床，并培养一代新的免疫工程从业人员。